Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

Thumbnail

New guidelines focus on the management of heart failure patients with secondary mitral regurgitation

The Heart Failure Association, European Association of Cardiovascular Imaging, European Heart Rhythm Association and European Association of Percutaneous Cardiovascular Interventions all collaborated on the position statement.

Thumbnail

Edwards evaluating the safety, effectiveness of new mitral valve repair solution

The system was designed to require only one small incision to repair a patient’s mitral valve. 

Thumbnail

Promising outcomes reported for transcatheter mitral valve-in-valve replacement

The overall procedural technical success rate, researchers reported, was 96.8%.

Thumbnail

CV societies ‘very concerned’ about proposed coverage changes for MR therapy

The American College of Cardiology, Society of Thoracic Surgeons, American Association for Thoracic Surgery and Society for Cardiovascular Angiography and Interventions all collaborated on the response. 

Thumbnail

Is volume an accurate measure of success when it comes to mitral valve surgery?

Nearly 93% of the U.S. population lives in a hospital referral region with at least one medical center that performs 25 or more mitral valve repairs or replacements each year, according to work published in JAMA Cardiology—but MVRR centers continue to suffer from significant geographical and patient-level disparities.

Thumbnail

TMVR with MitraClip increases life expectancy—at a cost

An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

3-year COAPT results bolster MitraClip’s success

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.